Artiva Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $363.9M
- Price
- $7.49
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.98%
- Volume
- 511.7K
About
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Quick stats
Shares outstanding48.6M
Computed float13.6M
Float / shares28.1%
Cash runway (months)38
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001817241
Websitehttps://www.artivabio.com
AI Summary
AI-generated1/19
minorbullishclinical trial
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Artiva Biotherapeutics will present updated clinical data on AlloNK (AB-101) in an oral presentation at the 17th International Symposium on Sjögren's Disease, held September 29 to October 2 in Paris.
The abstract, presented October 1 by Guillermo J. Valenzuela, M.D., covers AB-101 combined with rituximab generating robust efficacy responses in 11 patients with Sjögren disease.
AlloNK is Artiva's lead asset; the company is initiating a Phase 3 registrational trial in refractory rheumatoid arthritis in the second half of 2026 and is also evaluating AlloNK in Sjögren disease, systemic sclerosis, and myositis.